Oxaliplatin-based Chemotherapy: A New Option in Advanced Hepatocellular Carcinoma. A Systematic Review and Pooled Analysis

Clinical Oncology

Volumn 26, Issue 8, 2014, Pages 488-496

  Petrelli, F ^a   Coinu, A ^a   Borgonovo, K ^a   Cabiddu, M ^a   Ghilardi, M ^a   Lonati, V ^a   Barni, S ^a  

^a TREVIGLIO HOSPITAL   (Italy)

Author keywords

Advanced HCC; Chemotherapy; First line; Oxaliplatin; Sorafenib

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; OXALIPLATIN; SORAFENIB; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADVANCED HEPATOCELLULAR CARCINOMA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; DIARRHEA; DRUG FATALITY; HEMATOLOGIC DISEASE; HUMAN; LIVER CELL CARCINOMA; LIVER TOXICITY; META ANALYSIS; METASTASIS; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL (TOPIC); LIVER NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; HUMANS; LIVER NEOPLASMS; ORGANOPLATINUM COMPOUNDS;

EID: 84903820481     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2014.04.031     Document Type: Article

References (40)

1. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. NEngl J Med 2008, 359(4):378-390.
2. Lai C.L., Wu P.C., Chan G.C., et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988, 62:479.
3. Gish R.G., Porta C., Lazar L., et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. JClin Oncol 2007, 25:3069.
4. Qin S., Bai Y., Lim H.Y., et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. JClin Oncol 2013, 31:3501.
5. Wang Z., Zhou J., Fan J., et al. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth. Expert Opin Investig Drugs 2009, 18(11):1595-1604.
6. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
7. Cochran W.G. The combination of estimates from different experiments. Biometrics 1954, 10:110-129.
8. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
9. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
10. Egger M., Davey Smith G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997, 315:629-634.
11. Duval S., Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000, 56:455-463.
12. He S.L., Shen J., Sun X.J., Zhu X.J., Liu L.M., Dong J.C. Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments. World J Gastroenterol 2013, 19(28):4552-4558.
13. Dhooge M., Coriat R., Mir O., et al. Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with B cirrhosis. Oncology 2013, 84(1):32-38.
14. Zaanan A., Williet N., Hebbar M., et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. JHepatol 2013, 58(1):81-88.
15. Sanoff H.K., Bernard S., Goldberg R.M., et al. Phase II study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma. Gastrointest Cancer Res 2011, 4(3):78-83.
16. Sun W., Sohal D., Haller D.G., et al. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer 2011, 117(14):3187-3192.
17. Coriat R., Mir O., Cessot A., et al. Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. Invest New Drugs 2012, 30(1):376-381.
18. Uhm J.E., Park J.O., Lee J., et al. Aphase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma. Cancer Chemother Pharmacol 2009, 63(5):929-935.
19. Asnacios A., Fartoux L., Romano O., et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 2008, 112(12):2733-2739.
20. Boige V., Raoul J.L., Pignon J.P., et al. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer 2007, 97(7):862-867.
21. Li S., Niu Z., Tian H., et al. Treatment of advanced hepatocellular carcinoma with gemcitabine plus oxaliplatin. Hepatogastroenterology 2007, 54(73):218-223.
22. Louafi S., Boige V., Ducreux M., et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007, 109(7):1384-1390.
23. Zhu A.X., Blaszkowsky L.S., Ryan D.P., et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. JClin Oncol 2006, 24(12):1898-1903.
24. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10(1):25-34.
25. Llovet J.M., Bustamante J., Castells A., et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999, 29(1):62-67.
26. Cantarini M.C., Trevisani F., Morselli-Labate A.M., et al. Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. Am J Gastroenterol 2006, 101(1):91-98.
27. Yeo W., Mok T.S., Zee B., et al. Arandomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. JNatl Cancer Inst 2005, 97:1532.
28. Parikh P.M., Fuloria J., Babu G., et al. Aphase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma. Trop Gastroenterol 2005, 26:115.
29. Louafi S., Boige V., Ducreux M., et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007, 109:1384.
30. Nowak A., Findlay M., Culjak G., Stockler M. Tamoxifen for hepatocellular carcinoma. Cochrane Database Syst Rev 2004, (3):CD001024.
31. Simonetti R.G., Liberati A., Angiolini C., Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997, 8(2):117-136.
32. Abou-Alfa G.K., Johnson P., Knox J.J., et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010, 304(19):2154-2160.
33. Cheng A.L., Kang Y.K., Lin D.Y., et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. JClin Oncol 2013, 31(32):4067-4075.
34. Kaseb A.O., Garrett-Mayer E., Morris J.S., et al. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology 2012, 82(2):67-74.
35. Llovet J.M., Decaens T., Raoul J.L., et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. JClin Oncol 2013, 31(28):3509-3516.
36. Pressiani T., Boni C., Rimassa L., et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann Oncol 2013, 24(2):406-411.
37. Yoon E.L., Yeon J.E., Lee H.J., et al. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. JClin Gastroenterol 2014 Mar, 48(3):e22-e29.
38. Llovet J.M., Di Bisceglie A.M., Bruix J., et al. Design and endpoints of clinical trials in hepatocellular carcinoma. JNatl Cancer Inst 2008, 100(10):698-711.
39. Verslype C., Rosmorduc O., Rougier P. ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(Suppl. 7):vii41-vii48.
40. [accessed 09.11.13]. http://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf.